Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial.
Por:
Rodriguez-Moreno, J, Sevillano, E, Fenor, M, Martin, R, Esteban, E, Fernandez, R, Pous, A, Gajate, P, Munoz-Langa, J, Vazquez-Estevez, S, de Velasco, G, Virizuela, J, Navarro, P, Ruiz-LLorente, S, Beltran, L, Rodriguez-Antona, C and Garcaa-Donas, J
Publicada:
1 mar 2019
Resumen:
Filiaciones:
HM Hosp, Ctr Integral Oncol HM Clara Campal, Madrid, Spain.
San Pedro de Alcantara Hosp, Med Oncol, Caceres, Spain.
Hosp Univ Cent Asturias, Oviedo, Spain.
IMQ Zorrotzaurre, Bilbao, Spain.
HUGTiP, Inst Catala Oncol, Badalona, Spain.
Hosp Univ Ramon y Cajal, Madrid, Spain.
Hosp Univ La Fe, Valencia, Spain.
Lucus Augusti Univ Hosp, Lugo, Spain.
Univ Hosp 12 Octubre, Dept Med Oncol, I 12, Madrid, Spain.
Hosp Virgen de la Macarena, Seville, Spain.
Barts Hlth NHS Trust, Dept Cellular Pathol, London, England.
Spanish Natl Canc Res Ctr CNIO, Madrid, Spain.
HM Hosp, Oncol Unit, Ctr Integral Oncol HM Clara Campal, Madrid, Spain.
|